Institutional Ownership
Cullinan Therapeutics Inc
CUSIP 230031106COMCGEMQ1 2026
13D / 13G Filings
40
Schedule 13D/13G on record
Beneficial Filers
18
Distinct reporting persons
Largest Stake
18.3%
Max % of class reported
Institutional Holders
167
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
40 filings · latest Mar 4, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Mar 4, 2026 | Kynam Capital Management, LP | 13G | 5.3% | 3.11M | SEC |
| 2 | Feb 17, 2026 | Biotechnology Value Fund L P | 13G/A | 10.0% | 5.92M | SEC |
| 3 | Jan 30, 2026 | The Vanguard Group | 13G | 5.6% | 3.30M | SEC |
| 4 | Nov 14, 2025 | Citadel Advisors LLC | 13G/A | 3.4% | 1.99M | SEC |
| 5 | Nov 14, 2025 | Lynx1 Capital Management LP | 13G/A | 9.8% | 5.77M | SEC |
| 6 | Nov 13, 2025 | Deerfield Mgmt, L.P. | 13G/A | 5.0% | 2.93M | SEC |
| 7 | Oct 30, 2025 | The Vanguard Group | 13G/A | 5.0% | 2.94M | SEC |
| 8 | Oct 10, 2025 | Lynx1 Capital Management LP | 13G/A | 14.5% | 8.55M | SEC |
| 9 | Aug 14, 2025 | Lynx1 Capital Management LP | 13G | 7.5% | 4.40M | SEC |
| 10 | Aug 6, 2025 | Citadel Advisors LLC | 13G | 5.1% | 3.01M | SEC |
30 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Cullinan Therapeutics Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Lynx1 Capital Management LP | 8.96M | $127.37M |
| 2 | Mpm Bioimpact LLC | 7.65M | $108.68M |
| 3 | Bvf Inc/Il | 5.75M | $81.72M |
| 4 | Blackrock, Inc. | 4.45M | $63.23M |
| 5 | Kynam Capital Management, LP | 3.11M | $44.25M |
| 6 | State Street Corp | 2.54M | $36.15M |
| 7 | Blue Owl Capital Holdings LP | 1.91M | $27.14M |
| 8 | Rtw Investments, LP | 1.71M | $24.24M |
| 9 | Venrock Adviser, LLC | 1.38M | $19.61M |
| 10 | Geode Capital Management, LLC | 1.37M | $19.45M |